Ariceta Iraola G, Rodríguez Soriano J, Vallo Boado A, Quintela Pérez M J, Oliveros Pérez R
Departamento de Pediatría, Hospital de Cruces y Facultad de Medicina de la Universidad del País Vasco, España.
An Esp Pediatr. 1997 Sep;47(3):273-8.
Cyclosporin A (CyA) has been used in steroid-dependent and steroid-resistant nephrotic syndrome (NS) with the aim to prolong or to induce remission, respectively.
The efficacy and side-effects of CyA therapy were evaluated in 25 children with idiopathic NS. Twelve patients had steroid-dependent NS and 13 patients had steroid-resistant NS. In all cases, CyA was given as a third alternative drug, once therapies with prednisone and alkylating agents had failed. In steroid-resistant patients CyA administration was always associated with low-dose prednisone.
All 12 patients with steroid-dependent NS entered into remission during CyA administration, but 7 patients relapsed when the drug was withdrawn or tapered and 7 of 8 patients requiring long-term therapy continued to present new relapses. Prednisone requirement was lower and growth velocity higher during the year on CyA therapy than during the year preceding CyA therapy. Only 5 of the 13 patients with steroid-resistant NS had a complete remission. Three of these patients relapsed upon cessation of therapy, but these relapses became steroid-sensitive. Clinical side-effects (hirsutism, gum hyperplasia, arterial hypertension) were only observed in a few patients. Biochemical side-effects (hyperuricemia, hypomagnesemia) were more frequently observed, but always reverted upon cessation of therapy. The development of osteosarcoma in one patient may represent a coincidental finding.
The results suggest that CyA therapy is capable of inducing remission in all patients with steroid-dependent NS and in about one third of patients with steroid-resistant NS. However, most patients relapse when the CyA is stopped and require long-term therapy, often associated with administration of predisone.
环孢素A(CyA)已分别用于激素依赖型和激素抵抗型肾病综合征(NS),目的是延长缓解期或诱导缓解。
评估了25例特发性NS患儿CyA治疗的疗效和副作用。12例为激素依赖型NS患者,13例为激素抵抗型NS患者。在所有病例中,一旦泼尼松和烷化剂治疗失败,CyA作为第三种替代药物使用。在激素抵抗型患者中,CyA给药始终与小剂量泼尼松联合使用。
所有12例激素依赖型NS患者在CyA给药期间均进入缓解期,但7例患者在停药或减药时复发,8例需要长期治疗的患者中有7例继续出现新的复发。与CyA治疗前一年相比,CyA治疗期间患者对泼尼松的需求量更低,生长速度更高。13例激素抵抗型NS患者中只有5例完全缓解。其中3例患者在治疗停止后复发,但这些复发对激素变得敏感。仅在少数患者中观察到临床副作用(多毛症、牙龈增生、动脉高血压)。生化副作用(高尿酸血症、低镁血症)更常被观察到,但在停药后总是会恢复。1例患者发生骨肉瘤可能是偶然发现。
结果表明,CyA治疗能够使所有激素依赖型NS患者以及约三分之一的激素抵抗型NS患者诱导缓解。然而,大多数患者在停用CyA时复发,需要长期治疗,通常与泼尼松给药相关。